Tafluprost Solution/ Drops
NDC Package 42571-264-73

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Other Packages
    3. Frequently Asked Questions

Package Information

Tafluprost (tafluprost opthalmic) solution/ dropses is tafluprost ophthalmic solution, 0.0015% is indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. This formulation utilizes a solution/ drops delivery system. Marketed by Micro Labs Limited, this product is identified by NDC 42571-264 and is authorized under FDA application ANDA209051.

Identification & Billing

NDC Package Code
42571-264-73
Package Description
2 POUCH in 1 CARTON / 15 VIAL in 1 POUCH / .3 mL in 1 VIAL
Product Code
42571-264
11-Digit Billing Format
42571026473
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
1 EA
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Tafluprost
Non-Proprietary Name
Tafluprost Opthalmic
Substance Name
Tafluprost
Dosage Form
Solution/ Drops - A solution which is usually administered in a drop-wise fashion.
Administration Route
Ophthalmic - Administration to the external eye.
Active Ingredient(s)
TAFLUPROST .0045 mg/.3mL
Pharmacologic Class
Usage Information
Tafluprost ophthalmic solution, 0.0015% is indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Regulatory & Marketing

Labeler Name
Micro Labs Limited
Product Type
Human Prescription Drug
FDA Application #
ANDA209051
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
11-18-2022
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (42571-264). Click a package code to view its specific billing and regulatory data.

42571-264-26
1 POUCH in 1 CARTON / 15 VIAL in 1 POUCH / .3 mL in 1 VIAL
42571-264-74
6 POUCH in 1 CARTON / 15 VIAL in 1 POUCH / .3 mL in 1 VIAL

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 42571-264-73 identifies a specific commercial package of 2 pouch in 1 carton / 15 vial in 1 pouch / .3 ml in 1 vial of Tafluprost, a human prescription drug labeled by Micro Labs Limited. This solution/ drops is formulated for ophthalmic use and contains tafluprost as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Micro Labs Limited on November 18, 2022. The current certification is valid through December 31, 2027.

How is this Micro Labs Limited product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 42571026473. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 1 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
42571-264-73
11-Digit CMS (5-4-2)
42571-0264-73

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.